2023
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar T, Atallah E, Shallis R, Saliba A, Patel A, Bewersdorf J, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg A, Abaza Y, Murthy G, Kota V, Litzow M. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia 2023, 37: 799-806. PMID: 36807649, DOI: 10.1038/s41375-023-01847-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMiddle AgedRetrospective StudiesSalvage TherapyTransplantation ConditioningTransplantation, HomologousTumor Suppressor Protein p53ConceptsEvent-free survivalAllo-HSCTOverall survivalChronic GVHDAllogeneic hematopoietic stem cell transplantAllogeneic stem cell transplantationMedian event-free survivalHematopoietic stem cell transplantAcute myeloid leukemia patientsMedian overall survivalPost allo-HSCTReduced intensity conditioningStem cell transplantStem cell transplantationLong-term outcomesMyeloid leukemia patientsMulti-center studyAcute graftComplete remissionHost diseaseSalvage therapyComplex cytogeneticsMyeloablative conditioningMedian ageCell transplant
2022
Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia
Badar T, Litzow M, Shallis R, Patel A, Saliba A, Burkart M, Bewersdorf J, Stahl M, De Camargo Correia G, Murthy S, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg A, Palmisiano N, Al Kali A, Atallah E. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia. Cancer 2022, 129: 934-945. PMID: 36545710, DOI: 10.1002/cncr.34604.Peer-Reviewed Original ResearchMeSH KeywordsBlack PeopleHealthcare DisparitiesHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteRetrospective StudiesTumor Suppressor Protein p53White PeopleConceptsAcute myeloid leukemiaAllogeneic stem cell transplantationNHB patientsStem cell transplantationNHW patientsCell transplantationMyeloid leukemiaTherapy-related acute myeloid leukemiaNon-Hispanic black patientsCurative-intent therapyLow-intensity chemotherapyBest supportive careComplete response rateMedian patient ageProportion of patientsSubset of patientsDisease-directed therapyHigher proportionIntensive chemotherapyPatient ageSupportive careBlack patientsClinical outcomesTreatment disparitiesRetrospective studyMolecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
Stahl M, Derkach A, Farnoud N, Bewersdorf J, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel M, Cai S, Miles L, Bowman R, Geyer M, Dunbar A, Epstein‐Peterson Z, McGovern E, Schulman J, Glass J, Taylor J, Viny A, Stein E, Getta B, Arcila M, Gao Q, Barker J, Shaffer B, Papadopoulos E, Gyurkocza B, Perales M, Abdel‐Wahab O, Levine R, Giralt S, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman M, Roshal M, Goldberg A. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American Journal Of Hematology 2022, 98: 79-89. PMID: 36251406, PMCID: PMC10080561, DOI: 10.1002/ajh.26757.Peer-Reviewed Original ResearchMeSH KeywordsHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteNeoplasm, ResidualPrognosisRemission InductionStem Cell TransplantationTransplantation, HomologousConceptsMeasurable residual diseaseAcute myeloid leukemiaAllo-SCTInduction chemotherapyPersistent diseaseMyeloid leukemiaAllogeneic stem cell transplantationStem cell transplantationMonosomy 5Residual diseaseDisease clearanceKaryotypic abnormalitiesPrognostic factorsCell transplantationMolecular predictorsMRD clearanceRemissionClinical trialsNext-generation sequencingChemotherapyPatientsMutation patternsTherapyLeukemiaMRDOutcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival
Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American Journal Of Hematology 2022, 97: e232-e235. PMID: 35338673, DOI: 10.1002/ajh.26546.Peer-Reviewed Original ResearchAzacitidine maintenance in AML post induction and posttransplant
Bewersdorf JP, Prebet T, Gowda L. Azacitidine maintenance in AML post induction and posttransplant. Current Opinion In Hematology 2022, 29: 84-91. PMID: 35013047, DOI: 10.1097/moh.0000000000000700.Peer-Reviewed Original ResearchMeSH KeywordsAzacitidineHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteRecurrenceRemission InductionConceptsDisease-free survivalPostremission therapyAcute myeloid leukemiaAllo-HCTCC-486Allogeneic hematopoietic cell transplantNonrelapse mortality riskOverall survival benefitHematopoietic cell transplantDuration of remissionSubset of patientsRobust study designsAML trialsAzacitidine maintenanceInduction therapySurvival benefitAML patientsCell transplantDisease relapseRelapse reductionRelapse riskMyeloid leukemiaCommon causeSelect populationMortality risk
2021
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.Peer-Reviewed Original ResearchMeSH KeywordsFms-Like Tyrosine Kinase 3Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMyelodysplastic SyndromesProtein Kinase InhibitorsConceptsAcute myeloid leukemiaRelapse-free survivalMaintenance therapyMyelodysplastic syndromeFLT3 inhibitorsAllo-HCTHazard ratioMaintenance treatmentClinical trialsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationControl groupSystematic reviewAllogeneic hematopoietic cell transplantMeasurable residual disease statusHematopoietic stem cell transplantationMeasurable residual disease testingNon-relapse mortalityHematopoietic cell transplantPre-emptive treatmentResidual disease statusStem cell transplantationFavorable safety profileSame patient cohortRandom-effects modelVenetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 2021, 62: 3394-3401. PMID: 34477024, PMCID: PMC9012492, DOI: 10.1080/10428194.2021.1966788.Peer-Reviewed Original ResearchMeSH KeywordsBridged Bicyclo Compounds, HeterocyclicHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteRetrospective StudiesSulfonamidesConceptsAcute myeloid leukemiaAllogeneic hematopoietic cell transplantAllo-HCTHematopoietic cell transplantSalvage therapyMyelodysplastic syndromeCell transplantMemorial Sloan-Kettering Cancer CenterHigh-risk myelodysplastic syndromeSecond allo-HCTSalvage treatment optionOverall response rateMedian followMedian OSVenetoclax therapyRetrospective studyCancer CenterTreatment optionsOS estimatesMyeloid leukemiaPatientsResponse rateTherapyTransplantMonthsMaintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept
Bewersdorf J, Tallman M, Stahl M. Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. Current Opinion In Oncology 2021, 33: 658-669. PMID: 34341323, DOI: 10.1097/cco.0000000000000778.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAzacitidineHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaintenance ChemotherapyRandomized Controlled Trials as TopicConceptsAcute myeloid leukemiaAcute myeloid leukemia patientsMaintenance therapyAllo-HCTOverall survivalIntensive chemotherapyMyeloid leukemiaPersistence of leukemic cellsSafety of maintenance therapyAllogeneic hematopoietic cell transplantationRelapse-free survivalDuration of remissionHematopoietic cell transplantationIndividualized therapeutic approachFLT3 inhibitor sorafenibCC-486Induction chemotherapyOS benefitDisease relapseCell transplantationInhibitor sorafenibImproved survivalPatient selectionTargeted agentsLeukemic cellsOutcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.Peer-Reviewed Original ResearchMeSH KeywordsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansPrimary MyelofibrosisRetrospective StudiesTransplantation ConditioningConceptsConditioning regimen intensityAllo-HCTRegimen intensityChronic graftTransplant characteristicsGraft failureOverall survivalPatient ageSubgroup analysisDynamic International Prognostic Scoring System scoresSystematic reviewAllogeneic hematopoietic cell transplantationInternational Prognostic Scoring System scoreCurative therapeutic modalityNon-relapse mortalityTransplant-related mortalityMedian patient ageOutcomes of patientsSecondary graft failureCo-primary outcomesHematopoietic cell transplantHematopoietic cell transplantationRandomized clinical trialsHeterogeneity of patientsRandom-effects model
2020
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP, Zeidan AM. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Leukemia & Lymphoma 2020, 61: 2295-2312. PMID: 32421403, PMCID: PMC7670856, DOI: 10.1080/10428194.2020.1761968.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntimetabolites, AntineoplasticAzacitidineHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMyelodysplastic SyndromesConceptsHigh-risk myelodysplastic syndromeAcute myeloid leukemiaMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationGenetic testingHematopoietic stem cell transplantationImmune checkpoint inhibitorsCurative treatment optionMainstay of therapyRecent therapeutic advancesStem cell transplantationCurrent treatment approachesAgent azacitidineCheckpoint inhibitorsMost patientsMDS patientsAvailable therapiesCell transplantationPatient subgroupsTreatment optionsTherapeutic advancesIDH inhibitorsIndividualized treatmentNew agentsEvolving therapies for lower-risk myelodysplastic syndromes
Bewersdorf JP, Zeidan AM. Evolving therapies for lower-risk myelodysplastic syndromes. Annals Of Hematology 2020, 99: 677-692. PMID: 32078008, DOI: 10.1007/s00277-020-03963-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnemiaBlood TransfusionChelation TherapyClinical Trials as TopicCri-du-Chat SyndromeDrugs, InvestigationalForecastingHematinicsHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsIron OverloadLenalidomideMolecular Targeted TherapyMulticenter Studies as TopicMyelodysplastic SyndromesPrecision MedicinePrognosisRisk AssessmentSeverity of Illness IndexConceptsInternational Prognostic Scoring SystemLow-risk MDS patientsMyelodysplastic syndromeMDS patientsLower-risk myelodysplastic syndromesPrognostic scoring systemRisk stratification toolAdvanced clinical testingSymptomatic anemiaStratification toolHematologic malignanciesCurrent treatmentTherapeutic approachesNew agentsNew drug approvalsTherapeutic conceptsClinical developmentPatientsClinical testingMolecular pathogenesisScoring systemTherapeutic landscapePromising agentDrug approvalGenetic features
2019
One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant
Bewersdorf JP, Stahl M, Zeidan AM. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. Expert Review Of Hematology 2019, 12: 575-578. PMID: 31225770, DOI: 10.1080/17474086.2019.1635005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntigens, CDAzacitidineCD8-Positive T-LymphocytesClinical Trials as TopicDrug Therapy, CombinationFemaleHematopoietic Stem Cell TransplantationHumansLenalidomideLeukemia, Myeloid, AcuteLymphocyte Activation Gene 3 ProteinMaleMiddle AgedMyelodysplastic SyndromesProgrammed Cell Death 1 ReceptorRecurrenceTransplantation, HomologousConceptsAcute myeloid leukemiaHematopoietic stem cell transplantStem cell transplantMyelodysplastic syndromeMyeloid leukemiaAllo-HSCTCell transplantAllogeneic hematopoietic stem cell transplantResponse rateAllogeneic stem cell transplantationNovel salvage therapiesPhase Ib studyStem cell transplantationOverall response rateCycles of treatmentCases of graftHigh response rateMechanism of actionCombination lenalidomideSalvage therapyHost diseaseMost patientsCurative treatmentCombination therapyDisease stageHealthcare expenses for treatment of acute myeloid leukemia
Bewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsCost-Benefit AnalysisHealth Care CostsHematopoietic Stem Cell TransplantationHospitalizationHumansLeukemia, Myeloid, AcuteConceptsHematopoietic stem cell transplantInsurance statusHealthcare costsTreatment approachesAllogeneic hematopoietic stem cell transplantAcute myeloid leukemia (AML) treatmentStem cell transplantTreatment costsDirect healthcare costsInpatient treatment costsPatient insurance statusPersonalized treatment approachesAcute myeloid leukemiaMyeloid leukemia treatmentInfluence health policyIntensive chemotherapyOral therapyCell transplantMain cost driversMyeloid leukemiaNovel agentsMedical outcomesLeukemia treatmentHealthcare resourcesAML